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than 5 years.4 With the widespread availability of eﬀ ective 
rotavirus vaccines, the burden of norovirus-induced 
gastroenteritis will inevitably increase, especially in 
children. In fact, in countries where universal vaccination 
against rotavirus disease has been introduced and under-
taken for more than 2 years, norov iruses have become 
the main cause of acute gastroenteritis in children.9–11 
Therefore the study by Ahmed and colleagues4 supports 
the endeavors to develop norovirus vaccines. Large 
challenges still exist in the development of vaccine 
strategies that would provide broadly cross-protective 
immune responses. The inability to propagate human 
norovirus in cell culture has substantially hindered the 
identiﬁ cation of neutralising antibody epitopes, although 
these restrictions have been partly overcome. Thus, 
the development of a universal, probably multivalent 
norovirus vaccine might be well within reach.12 This 
development makes research on norovirus biology, virus–
host associations, epidemiology, and evolution much 
more important.
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Severe neonatal bacterial infections: when numbers matter
In May this year, the World Health Assembly endorsed 
the Every Newborn Action Plan—the ﬁ rst global plan 
to end preventable deaths in newborn babies and 
stillbirths.1,2 Melinda Gates assured the delegates at the 
Assembly that the Bill & Melinda Gates Foundation is 
committed to the “triple investment” of preventing 
maternal and newborn deaths and stillbirths,2 and The 
Lancet has published the Every Newborn Series. 
These initiatives should be seen in the context of the 
eﬀ orts to achieve the Millennium Development Goal, 
during which child mortality (<5 years of age) has been 
halved but neonatal mortality reduced by only a third. 
Neonatal mortality now accounts for 2·9 million (44%) 
childhood deaths.3 Of the neonatal deaths about a third 
are caused by infection.4
Deriving the number of serious bacterial infections 
in infants younger than 1 month is complex. Many 
countries do not register all births and deaths, making 
it diﬃ  cult to establish the denominator (livebirths). 
Neonatal sepsis is diﬃ  cult to diagnose: the signs can 
be subtle and non-speciﬁ c, and in settings where little 
or no laboratory support exists and clinical care is basic, 
the diagnosis is especially hard. Clinical diagnostic 
algorithms are biased towards sensitivity rather than 
speciﬁ city, because neonates can deteriorate with 
alarming speed.5 Even in high-income countries with 
the advantage of ancillary tests, the diagnosis can be 
problematic. 
There are no global estimates of the rates of neonatal 
sepsis, only of deaths. In The Lancet Infectious Diseases, 
Anna Seale and colleagues6 present ﬁ ndings from 
a systematic review and meta-analysis to estimate 
the number of possible serious bacterial infections 
and deaths in male and female neonates in sub-
Saharan Africa, south Asia, and Latin America. Their 
systematic review identiﬁ ed only six studies that met 
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their eligibility criteria, with most studies ineligible 
because denominators were not available. The study 
group provided data from a further 18 secondary 
analyses and unpublished studies. Despite diﬀ erences 
in study design, diagnostic criteria, and follow-up, 
their estimates are fairly robust. They conclude that in 
2012, there were 6·9 million cases (uncertainty range 
5·5 million–8·3 million) of possible severe bacterial 
infection in neonates of 32 weeks of gestation or 
more or weighing 1500 g or more at birth, of whom 
680 000 died (0·46 million–0·92 million). The overall 
incidence was 7·6% (95% CI 6·1–9·2) and case-fatality 
was 9·8% (7·4–12·2). Latin America had the highest 
incidence (9·2%) but lowest death rate (7·4%), and sub-
Saharan Africa had the lowest incidence (6·2%) and 
highest case-fatality rate (12·2%). 
What should be done to stop so many babies having 
possible severe bacterial infection? First, protecting babies 
starts with looking after their mothers. There should 
be seamless care from the antenatal period through to 
childhood. Examples are maternal immunisation against 
tetanus, group B streptococcus prophylaxis, prevention 
of prematurity and subsequent increased risk of late 
neonatal sepsis, and prevention of HIV transmission. 
Second, deliveries should be clean, safe, and attended 
by a skilled assistant; cord cleansing with chlorhexidine 
should be done (ﬁ ndings from a meta-analysis of three 
randomised community-based cluster trials done in south 
Asia between 2002  and 2010, including 54 624 newborn 
babies, showed that such care led to a 23% reduction in 
all-cause neonatal mortality: deaths from omphalitis fell 
by 27–56%);7 and frequent hand washing by all involved in 
assisting the delivery and handling the baby. 
Third, there should be early and exclusive breast-
feeding, babies should be kept warm, and danger 
signs (eg, abnormal temperature, poor feeding, 
diﬃ  culty breathing, little spontaneous movement, and 
convulsions) should be identiﬁ ed early, with rapid access 
to appropriate treatment. None of these interventions 
are new or costly.
Who should get antibiotics and where should they 
get them? Globally, clinicians have a low threshold 
for giving sick infants antibiotics, with most tending 
to overtreat. WHO recommends empirical treatment 
with either ampicillin or penicillin plus gentamicin, and 
although ﬁ ndings from studies show these options to be 
appropriate for most community-acquired infections, 
there is an increase in the incidence of Klebsiella spp 
and Staphylococcus spp infections, which are resistant 
to this combination of drugs.8 There are ongoing 
community-based trials in Africa and south Asia in which 
combinations of parental or oral antibiotics, based on 
the WHO recommendations, are being given to assess 
the safety and eﬃ  cacy of out of hospital antibiotic 
treatment.9 Will overuse of these empirical antibiotics 
lead to further increases in antibiotic resistance and 
increased cost of treatment?10
What is needed—worldwide—is a simple bedside 
test to diﬀ erentiate bacterial from other infections; at 
present, all that is available for clinical use is C-reactive 
protein, which is not reliable in neonates.11 Attempts 
at ﬁ ne tuning clinical scores have not made much 
diﬀ erence.
Mortality must decrease but not at the cost of more 
children with disabilities. Quality of care must improve. 
Findings from a study of neonatal care in ﬁ rst-referral 
hospitals in India showed a large discrepancy between 
knowledge (eg, 78% for resuscitation) and skill (24%).12 
Training needs to be eﬀ ective, facility-based, and 
monitored, and should have ongoing supervision. All 
of this takes political commitment—but, as shown in 
The Lancet’s Every Newborn Series, only a very small 
proportion of donor funds is speciﬁ cally for neonatal 
babies. It is time for change.
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An international crisis of multidrug-resistant and 
pan-drug-resistant bacteria is rapidly progressing.1,2 
Although work to develop new antibiotics continues, 
it is not known whether there will be drugs with novel 
mechanisms of action against highly resistant Gram-
negative organisms in the foreseeable future.3 Use of 
an antibiotic in one person has the potential to aﬀ ect 
the drug’s eﬃ  cacy in others, making the overuse of 
antibiotics a public health problem worldwide. It is 
time for a global solution. Antibiotic consumption 
across all countries should be quantiﬁ ed and compared 
so that the race to be a country with low antibiotic use 
can begin.
In The Lancet Infectious Diseases, Thomas Van 
Boeckel and colleagues assembled and analysed data 
to estimate the international total sales of antibiotic 
drugs.4 They examined sales of 16 antibiotic drug 
classes between 2000 and 2010 in 71 countries with use 
of data obtained from the IMS Health MIDAS database 
(IMS Health, Danbury, CT, USA). The authors report 
that antibiotic sales have increased by about 36%, with 
the largest increases occurring in low-income countries 
in which antibiotic drugs can be accessed without 
prescription.4 Van Boeckel and colleagues’ eﬀ orts 
should be applauded. Understanding gained from 
international variations in antibiotic use will inform 
where initiatives should focus eﬀ orts for judicious 
prescribing. The sharing of antibiotic sales data could 
allow low-antibiotic-consuming countries to mentor 
high-antibiotic-consuming countries about eﬀ ective 
practices and policies that foster rational antibiotic use. 
Without doubt, the IMS data have limitations. Data 
sources are probably more robust and reliable for some 
countries than for others. The authors compared data 
for antibiotic sales from IMS to data for antibiotic 
consumption from the European Surveillance of 
Antimicrobial Consumption Network and reported 
reasonable concordance in prescribing rates for the 
29 European countries; however, no alternative 
surveillance networks exist in other parts of the world to 
make the equivalent comparisons. In addition, the exact 
relation between antibiotic sales and actual use, what 
proportion of antibiotic use is for appropriate indications, 
or how these measures might diﬀ er across countries is 
not known. Despite these limitations, the absence of 
alternative data sources and the urgency to quantify 
antibiotic use to guide interventions lends great value to 
this imperfect data for international antibiotic use. 
Perhaps diﬀ erences in antibiotic sales from country 
to country should be expected. Countries with large 
impoverished populations who are challenged by 
compromised sanitation practices and poor access 
to vaccines are at greater risk for bacterial infections 
and might need larger quantities of antibiotics than 
other, more developed, countries. Although some 
degree of variation is expected, should this much be 
expected? Should India have ten-time more sales of 
cephalosporins per person compared with Germany? 
Diﬀ erences between sales in northern European 
countries and the USA, which have similar income 
and resources, suggest patterns of antibiotic sales 
that are not simply related to the baseline health of 
the population, but rather to other drivers such as 
prescriber and patient habits, the presence of national 
regulations that aﬀ ect antibiotic prescribing, and 
marketing practices of pharmaceutical companies.
Of course, it is not always clear if antibiotic con-
sumption is a cause or consequence of antimicrobial 
resistance. Irrespective, if a country’s antibiotic sales data 
are above the international median, a plan to assess the 
causes and improve prescribing should be deployed. This 
task might sound daunting, but it can be done. In 2002 
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